Vue's £1.5bn IPO Ask Is a Supply-Side Bet, Not Just a Recovery Story

Vue International, Europe's largest independent cinema operator, is moving toward a London stock-market listing, and the one number that defines the whole opportunity is the price tag attached to the process: between £1 billion and £1.5 billion. After hiring Rothschild to explore exit options, the company is now reported to be leaning toward an IPO next year. That vaults Vue into a strange category for most U.S. investors — a household name in British high streets that has no ticker, no public filings you can trade, and a valuation that exists only in the bankers' pitch.

To understand what that price is really asking for, it helps to know what got Vue to this point. The company spent years in what its chief executive calls "six years of hell". COVID emptied the multiplexes, then the industry had to survive a 2023 film-slate collapse after the Hollywood writers' and actors' strikes caused production delays that pushed a number of titles off the 2023 and 2024 release calendars. Vue went through a debt restructuring in early 2023, which removed roughly £470 million of debt from the balance sheet and added £75 million in liquidity — and in exchange, control shifted to its lenders, led by private-credit firm Barings and hedge fund Farallon Capital. A year later it was back in talks with shareholders and lenders over another potential debt-for-equity restructuring.

In other words, the people pushing for a listing are not the people who built the business; they are the funds that took it over when it nearly collapsed. Debt investors whose claims became equity are sitting on a private asset they must eventually exit. A sale or an IPO is the exit. That is the mechanism underneath all the good news, and it matters for what a retail buyer would actually be buying.

Now the good news is real. Vue runs about 225 sites and 2,001 screens across eight countries. After the blockbuster summer and a strong content pipeline, its CEO says cinema is "back completely", and in April 2026 S&P Global Ratings upgraded the company to 'B-' — still deep in junk territory, but an upgrade — citing the box office recovery driving recovering profitability, deleveraging, and improving free operating cash flow, partially offset by higher interest costs.

Here is the hard part of the valuation, and it is the part that should give a prospective buyer pause. The £1 billion-to-£1.5 billion range is roughly double the approximately £650 million the company was worth during the 2022 restructuring, when the chain was being written down after ticket sales collapsed. The whole premium rests on the recovery being durable rather than a good summer. And unlike a software business that compounds on retained customers, cinema is a supply business: revenue rises and falls on the film slate a given year produces, not on built-up switching costs. The bear case is not that people stopped liking movies — the strongest bear fact is that the industry's own consolidation threatens the supply. As Paramount Skydance beat Netflix in the race to buy Warner Bros. Discovery, U.K. cinemas cautiously welcomed the move but worried the combined studio would greenlight fewer theatrical releases. Fewer movies means fewer reasons to sit in a Vue seat, regardless of how strong this quarter feels.

For an investor treating Vue as a watch-list name rather than a trade, the gate is the multiple on normalized box office, not the record summer. The two things that make the ask price hold up are exactly the two things in tension: the debt has to keep coming down while free cash flow has to prove it can survive a year when the slate is thin, and the higher interest bill on that still-substantial debt is a direct deduction from the cash that the valuation implies. S&P's language hedges on precisely that — it expects the recovery to pay down leverage, but flags interest costs as the offset. That is the difference between a company that is simply worth more than it was at its worst and one that is actually worth £1.5 billion.

Until the listing is priced, there is no stock to judge, and no rating to give — this is a pre-IPO watch, not a position. But the framework for judging it later is already clear. The recovery part is real and, after its 2023 restructuring, the balance sheet is healthier than the narrative of a cinema chain in trouble suggests. The price part is unproven. A buyer of Vue at the top of that range is not just betting that attendance recovered; they are betting that Hollywood's consolidation does not thin out the one thing the entire model depends on — the movies.